Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials

Journal:
PLOS Medicine
Published:
DOI:
10.1371/journal.pmed.1004609
Affiliations:
5
Authors:
10
Go to article
Institutions Authors Share
ExeVir Bio BV., Belgium
6.000000
 0.60
PRA Health Sciences-Netherlands, Netherlands
1.000000
 0.10
Clinical Republican Hospital “Timofei Mosneaga”, Moldova
1.000000
 0.10
POG Pharmacometrics, United Kingdom (UK)
1.000000
 0.10
University Hospital of Liege, Belgium
1.000000
 0.10